netFormulary NHS
Coventry and Warwickshire Area Prescribing Committee

Enter drug (generic/brand) name(s)/product
or therapy area eg: hypertension
typing ‘partial words’ will enhance your search option

Useful Links

Latest APC Revisions: 2021 

updated: 13.07.21 

APC Newsletters2020-21

updated: 24.05.21 


Chapter 17: Primary care Antimicrobial guidance - click on tabs below
Notes section
 17.01: RAG rating prescribing 17.02: CNS infections 17.03: Dental infections
17.04: ENT infections 17.05: Eye infections 17.06:Gastrointestinal infections
17.07: Genital Tract infections 17.08: Parasitic infections 17.09: Respiratory Tract infections
17.10: Skin & Soft tissue infections 17.11: Urinary Tract infections 17.12: Viral infections


Warwickshire North:
Shared Care Agreements - level 2

Obtain current SCA(s) from this website DO NOT save document(s) as reguarly updated

Share Care Request Letter - 11/19

Prescription Request Clarification Form


Important:APC guidance

View Chapter 4.10

Drugs used in substance dependence


Email APC office: to request the following:

  • APC submission forms (email details of the reason for your request) 
  • Latest shared care agreement (SCA) template in 'word' version


CRCCG/WNCCG Over the Counter (OTC) Policy


News Feed

Medicines Supply information 2021 - updated 28th July  

Medicines Supply information (upto Dec 2020 - updated 29th December

July 2021 Price Concessions: 2nd update - updated 16.7.21

MHRA update: COVID-19 vaccines - updates for July 2021 updated 08.07.21

CAS Alert: Immediate Actions In Response To Mink-Variant Sars-Cov-2 Virus In Denmark added 12.11.20

MHRA Drug Safety Update (COVID-19) June 2020 - updated 04.08.20

Coronavirus (COVID-19): new dedicated Yellow Card reporting site for medicines -updated 27.05.20

CAS Alert: Covid-19 General Case Definition Change added 18.05.20

NICE COVID-19 Rapid guidelines and evidence summaries updated 19.08.20

NHS England Novel Coronavirus Alert - updated 13th March

Novel Coronavirus flowchart

NHS England Novel Coronavirus - Ibuprofen And Coronavirus (Covid-19)  updated 15th April


The Coventry & Warwickshire Formulary has been developed through wide consultation with stakeholders in both primary and secondary care which has delivered an initial version covering over 40 sections and sub-sections of the BNF. The formulary will be a dynamic list of drugs considered as the most cost-effective alternatives in each section, the decision underpinned by high grade evidence, and changes will be made as the evidence base alters and/or costs change.



Coventry & Warwickshire Prescribing Formulary - Overview
General considerations
A) Preferred, Second-line and Non-Formulary (Qualified) choices
  • The formulary has been designed to offer the prescriber sufficient evidence based and cost effective first line choices appropriate for the majority of clinical scenarios
  • Second line choices allow for specifically licensed and/or nationally guided options and together with the first line choices will give the prescriber scope to manage all but a few patients in each therapy area
  • Non-formulary (Qualified) choices are all other drugs in that BNF section which are considered unnecessary. However in rare circumstances they may be prescribed but the prescriber should justify this and record the selection in the patient record.
B) Specialist Drugs
These are important APC outputs as they guide all prescribers, in secondary and primary care, to those drugs which are considered as “specialist” and into which category they have been placed. The four categories are:  SI, SA, SC, SO  for explanation of these terms refer to netFormulary end pages when searching for drug/product entry. 
C) Liquid preparations
As a general principle licensed medicines should be used whenever possible. Where a patient has, for example, swallowing difficulties and cannot take solid dose medicines then licensed liquid/buccal/patch versions or other alternatives, for example, should be used instead. This may require a change to another product in the same class of medicine through a review of the patient's medication. When there is no alternative please consult the APC guidance on specials for alternative approaches including off label use of licensed products, e.g. dissolving solid dose versions in water, and, as a last resort, ordering unlicensed specials on prescription  -  view guidance in Chapter 18 "Primary care information" click on full section.
D) Generic v Branded

Prescribers should always default to the generic version of the drug, and the formulary uses the approved generic names for all preferred and second-line choices, except in the following circumstances;

  • Bioavailability variation between different manufacturers version sof a drug is clinically important, e.g. theophylline, diltiazem
  • Local decision makers have approved the use of a particular brand on the grounds of cost-effectiveness, e.g. Venlalic XL®
E) National QIPP indicators
Those drugs, prescribing of which is subject to scrutiny via a national QIPP indictor, are marked with the annotation below. In these areas prescribers need to give consideration either to the choice of drug, which is reflected in the preferred options e.g. NSAIDs, or the volume of prescribing of a class of drugs, e.g. high dose inhaled corticosteroids.




   Last updated: 28/07/2021 15:13:26
    Download net formulary from Apple IOS Store  Google Play net formulary